Information Provided By: 
Fly News Breaks for August 30, 2017
LJPC
Aug 30, 2017 | 05:09 EDT
JPMorgan analyst Anupam Rama started La Jolla Pharmaceutical with an Overweight rating and $36 price target. The shares at current levels are "fundamentally undervalued" given the "high probability" of LJPC-501 approval for the treatment of catecholamine-resistant vasodilatory shock, Rama tells investors in a research note. He views the asset as an "attractive and de-risked candidate" and estimates the peak sales opportunity at $600M-plus per year in the U.S. alone.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
